PCAR — PACCAR Inc

Market sentiment is cautiously mixed. Q2 2026 beat estimates with EPS of $1.43 versus roughly $1.36 expected and revenue of $7.55B versus ~$7.05B expected, and management guided to ~42,000 deliveries in Q3. However, the analyst consensus is still Hold, the stock is below its 20-day and 50-day moving averages as of 2026-08-27, and the 26.6x trailing P/E keeps valuation-focused investors cautious. Institutional support remains solid and price targets average around $132, but the immediate tape is not euphoric.

The data clearly show a cyclical downcycle that is now inflecting. Revenue fell from roughly $8.2-8.8B per quarter in 2024 to $6.23B in Q1 2026, then jumped 21% sequentially to $7.55B in Q2 2026. Gross margin compressed from around 20-21% in 2024 to 13.1% in Q1 2026, but snapped back to 16.1% in Q2 2026; operating margin similarly rebounded from 8.8% to 11.7%. EPS went from $2.27-$2.70 in early 2024 down to $0.96-$1.15 in the 2025/early-2026 trough, then improved to $1.43 in Q2 2026. This looks like an early cyclical recovery, not a structural decline, but the YoY comparisons are still only barely positive, so it is a young recovery.

As of 2026-08-27, PCAR at $126.54 is not cheap. It trades at 26.6x TTM EPS of $4.75 and 2.44x sales, well above its own 5-year averages of 15.3x earnings and 1.52x sales. Price-to-book is 3.28x, and the negative PEG ratio is a byproduct of depressed trailing earnings rather than a useful gauge. On next-FY consensus EPS of $5.93, the forward P/E is about 21.4x. That is a quality premium, but relative to its own history and the current stage of the cycle, the stock is priced rich.

The market is paying up for the recovery before it is fully visible in reported earnings. TTM EPS of $4.75 makes the trailing multiple look very expensive; forward estimates of $5.93 make it merely expensive. If the cycle normalizes toward $7-8 of EPS in 2027-2028, the current price would equate to roughly 16-18x more-normalized earnings, which is reasonable. The playbook, therefore, is to watch the quarterly execution: Q3 2026 guidance for ~42,000 deliveries and ~14.5% gross margin is the key near-term proof. If that holds, estimates rise and the stock can grow into its multiple. If it disappoints, the 26.6x trailing P/E leaves a lot of room to fall.

As of 2026-08-27, RSI was 42.63, which is neutral-to-soft rather than oversold. Price was 3.29% below the 20-day SMA and 0.5% below the 50-day SMA, but still 6.31% above the 200-day SMA. That suggests the medium-term uptrend is intact while short-term momentum has stalled. The stock is in a consolidation/pullback, with nearby resistance around $127-131. For entry timing, waiting for a reclaim of the 50-day on volume, or a deeper pullback toward the 200-day, would offer a better risk/reward than chasing here.

• North American Class 8 truck cycle: management forecasts US/Canada retail sales of 230,000-270,000 units in 2026, and improving freight rates are pulling orders back into the market.
• EPA 2027 NOx rule: regulatory clarity is encouraging some prebuy demand ahead of roughly $10,000 compliance-cost increases, boosting near-term orders but pulling future demand forward.
• Tariffs and trade policy: PACCAR is optimizing production across the US, Canada, and Mexico under Section 232, but tariff and supply-chain cost risks remain live.
• Interest rates and financing costs: rising Treasury yields pressure industrial valuations and affect PACCAR Financial Services revenue, while credit conditions matter for truck financing demand.
• Freight cycle and used-truck pricing: a stabilizing freight market and reduced trucking capacity are aiding replacement demand, but a stalled recovery would hit both new truck orders and PACCAR Financial asset values.

• Q3 2026 earnings in late October: management guided to ~42,000 deliveries and ~14.5% gross margin; actual results will confirm whether the recovery is real or a one-quarter blip.
• Regulatory prebuy ahead of EPA 2027 NOx rules could keep order books strong through late 2026 and early 2027.
• Capital allocation: PACCAR's strong cash generation raises the possibility of year-end/special dividends or continued regular dividend increases.
• Upward estimate revisions: post-Q2-beat revisions through 2028 could gain momentum if freight rates and order activity keep improving.

• The cyclical recovery could stall if freight rates soften again, leading to order cancellations and slower deliveries than guided.
• Valuation multiple compression: at 26.6x trailing EPS and 21.4x forward EPS, the stock has little room for disappointment.
• Regulatory prebuy hangover after 2027: pulled-forward truck demand could leave 2027-2028 comparisons depressed.
• Tariffs, trade policy, and input-cost inflation could squeeze margins despite PACCAR's manufacturing footprint optimization.
• PACCAR Financial Services faces credit risk if trucking end-markets deteriorate and used-truck values fall.

PACCAR is a high-quality, financially strong cyclical emerging from a severe downcycle, but the stock at $126.54 as of 2026-08-27 already prices in a meaningful recovery. The fundamental direction is improving, yet valuation leaves limited margin of safety unless the upcycle beats consensus estimates. This is a good company, but only a fair-to-slightly-rich stock right now.

Applied a justified forward P/E of 20x to consensus next-FY EPS of $5.926. The 20x multiple is a quality and cyclical-recovery premium to PACCAR's 5-year average trailing P/E of 15.3x, but it is below the stock's current 21.4x forward multiple, reflecting the assumption that 2027 consensus estimates are still below full mid-cycle earning power. This yields a fair value of $118.52.